Ralph J. Hauke - Concepedia

Author

Ralph J. Hauke

Also Known As

Habib Ghaddar, Hamid Emamekhoo, Joelle Hamilton, Nagla Karim, R Hauke, R J Hauke, R. Hauke, R. J. Hauke, R.J. Hauke, Ralph Hauke

247

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Nebraska Cancer Specialists University of Nebraska Medical Center Moffitt Cancer Center Indiana University – Purdue University Indianapolis Indiana University Health

About

Ralph J. Hauke is an author at Nebraska Cancer Specialists specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	23	1.5K
2	Health Sciences	5	5	321
3	Engineering	1	1	58
4	Nursing	1	1	91
5	Public Health	1	1	91

Ralph J. Hauke

Publications

3.6K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu, The Lancet Oncology First-line TherapyUrologyChemotherapy Versus ChemotherapyGenitourinary CancerMedicine	2021	627
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Thomas Powles, Piotr Tomczak, Se Hoon Park, The Lancet Oncology	2022	262
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance) Matthew R. Smith, Susan Halabi, Charles J. Ryan, Journal of Clinical Oncology	2014	246
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement Matthew I. Milowsky, R. Bryan Rumble, Christopher M. Booth, Journal of Clinical Oncology	2016	233
ERK inhibitor PD98059 enhances docetaxel‐induced apoptosis of androgen‐independent human prostate cancer cells Stanislav Zelivianski, Matthew Spellman, Mark Kellerman, International Journal of Cancer	2003	137
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer Samuel R. Denmeade, Hao Wang, Neeraj Agarwal, Journal of Clinical Oncology	2021	133
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial Charu Aggarwal, Amy Prawira, Scott Antonia, Journal for ImmunoTherapy of Cancer	2022	131
Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Matthew J. Resnick, Christina Lacchetti, Jonathan Bergman, Journal of Clinical Oncology	2015	124
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes Matthew D. Galsky, Huan Wang, Noah M. Hahn, European Urology Metastatic Urothelial CancerUrologyGenitourinary CancerMedicineClinical Trials	2017	113
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma Ajjai Alva, Gregory A. Daniels, Michael K. Wong, Cancer Immunology Immunotherapy	2016	102

Page 1